Experimental drug improves survival rate of majority of lung cancer patients compared

[News]

In global clinical trials, patients with advanced metastatic lung cancer who were treated with a targeted immunotherapy drug lived significantly longer and with fewer side effects than those who received standard second-line chemotherapy, according to a new Kaiser Permanente study published today in the journal The Lancet.

More... (http://www.news-medical.net/news/20160315/Experimental-drug-improves-survival-rate-of-majority-of-lung-cancer-patients-compared-to-standard-chemotherapy.aspx)